Why Nymox Pharmaceutical Took Off
Nymox Pharmaceutical shares made solid headway in Wednesday’s session on positive results from a cancer trial.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 207
Medgenics Announces Pricing of Secondary Offering
Medgenics saw its shares drop on Tuesday after the company announced the pricing of its secondary offering.
With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?
Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
US Health Care Expense Could Be $2.6 Trillion Below Forecast
Health care costs could be $2.6 trillion less from 2014 to 2019, well below earlier forecasts, according to the Robert Wood Johnson Foundation.
Global Blood Therapeutics Rises After Pricing Secondary Offering
Global Blood Therapeutics shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level.
4 Red-Hot Biotech Stocks With Over 100% Upside Potential
These four biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the past year, offering aggressive accounts the best entry points in some time.
Gilead Sciences Bounces on Preliminary Results
Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped about 17.5% so far…
Selecta Biosciences Closes in on IPO
Selecta Biosciences intends to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Syros Pharmaceuticals Announces Potential Pricing for IPO
Syros Pharmaceuticals expects to price 4 million shares in the range of $14 to $16 per share in an intial public offering valued up to more than $73 million.
How Inovio Pharma Is Joining the Fight Against the Zika Virus
Inovio Pharmaceuticals has announced that it received approval to initiate a Phase 1 human trial to evaluate its Zika DNA vaccine (GLS-5700) to prevent infection from the Zika virus.
Could This Be a Turning Point for Fate Therapeutics?
Shares of Fate Therapeutics saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval.
Paratek Makes Milestone Movement in Late-Stage Trial
Paratek Pharmaceuticals saw its shares take a solid jump early on Friday after the results from its late-stage trial were released.
Tonix Pharmaceuticals Prices Secondary Offering
Shares of Tonix Pharmaceuticals slid in Thursday’s session after the company announced the pricing of its secondary offering.
6 Biopharma Movers Making a Run on Wednesday
24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in the session.
Some Popular Obamacare Plans About to See Big Price Hikes?
Users of some popular Affordable Care Act plans may face sticker shock in the coming year, according to a study by the Kaiser Family Foundation released on Wednesday.